Comment from John Ellis
AnonymousOpposeIndividual
Summary: The commenter opposes the proposed action, arguing that removing access to compounded Tirzepatide will negatively impact public health. They contend that compounded versions are essential for making obesity and addiction medications affordable and accessible to a large portion of the American population.
President Trump’s stated health goals focus on the "Make America Healthy Again" (MAHA) initiative, aimed at reducing chronic disease, improving nutrition, and lowering healthcare costs. Access to compounded Tirzepatide is facilitating all three by lowering cost, and improving access to medication that fundamentally addresses obesity. Obesity impacts nearly 40% of American's and is a main contributor to diabetes, chronic inflammation and increased risk of cancer, stroke, and cardiovascular disease. Furthermore, GLP-1's are showing significant benefits in all areas of addiction which impact 49 million (16%) of Americans. Removing compounded Tirzepatide and the affordability that comes with it will negatively impact American's health and further worsen the health crises.